Roche Lazard Capital Markets 7 th Annual Healthcare Conference. Thomas Kudsk Larsen, 17 November 2010

Size: px
Start display at page:

Download "Roche Lazard Capital Markets 7 th Annual Healthcare Conference. Thomas Kudsk Larsen, 17 November 2010"

Transcription

1 Roche Lazard Capital Markets 7 th Annual Healthcare Conference Thomas Kudsk Larsen, 17 November 2010

2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website All mentioned trademarks are legally protected 2

3 Business update Pipeline highlights 3

4 Group: Sales YTD September 2010 Solid sales growth in first nine months YTD Sept YTD Sept change in % Excluding CHF bn CHF local Tamiflu* Pharmaceuticals Division Diagnostics Division Roche Group *in local currency 4

5 Diagnostics: Growth driven by Professional Diagnostics and Diabetes Care CHF bn YTD Sept 10 vs. YTD Sept 09 local growth Professional Dia +10% Nth America growing 10%; Sept US launch of Clinical chemistry modules for cobas 8000 modular analyzer series Diabetes Care +5% Strong above-market growth in EMEA 1 and LATAM 2 ; Driven by Accu-Chek Performa and Accu-Chek Aviva Molecular Dia +4% Strong placements of cobas 4800 systems ex-us; TaqScreen DPX Test (parvo B19 & HAV) received CE mark Applied Science +8% Robust up-take GS Junior DNA sequencer EU & APAC 3 ; Low H1N1 testing dampening reagent sales Tissue Dia +18% EMEA North America RoW Launched 4 new Abs in US as aid diagnosis various cancers; Acquired BioImagene Inc. to strengthen Digital Pathology Europe, Middle East, Africa 2 Latin America 3 Asia Pacific 5

6 Pharma: Sales YTD September change in % Excluding CHF m CHF m CHF local Tamiflu* Pharmaceuticals Division 29,034 28, United States 11,157 10, Western Europe 8,026 7, Japan 3,490 3, International 6,361 7, Quarterly growth rates Q1 Q2 Q3 Q4 Q1 Q2 Q3 Pharmaceuticals Division excl. Tamiflu % in LC vs. prior year *in local currency 6

7 Pharma: Major growth contributors* Oncology products driving growth AVASTIN 528 MABTHERA / RITUXAN HERCEPTIN LUCENTIS ACTEMRA XELODA TARCEVA MIRCERA NEORECORMON / EPOGIN CELLCEPT TAMIFLU *Absolute amounts in CHF m at 2009 exchange rates; products with contribution above CHF 50 m 7

8 Pharma: Late-stage pipeline progressing well Extensive clinical data by year-end Number of NMEs Virology CNS Metabolic Inflammation 10 RG1678 GRI up to 14 HCV pol inh 1 ocrelizumab MS 1 RG1678 GRI SGLT2 inh 2 aleglitazar AASLD ECTRIMS ACNP 5-9 Dec. Phase II in house Recruitment on track Oncology aleglitazar taspoglutide taspoglutide dalcetrapib Recruitment finalized 2 ocrelizumab Actemra 4 taspoglutide dalcetrapib ocrelizumab pertuzumab dalcetrapib ocrelizumab Hedgehog inh BRAF inhibitor T-DM1 RG7159 (CLL) pertuzumab lebrikizumab 2 MetMAb 1 Hedgehog inh BRAF inhibitor T-DM1 RG7159 (CLL, NHL) pertuzumab Phase II data expected in 2010 ESMO SMR/Intl. Melanoma Congress 4-9 Nov. ESMO Data in 2011 ASH 4-7 Dec. SABCS 8-12 Dec E 1 LIP decision made, phase III pending; 2 LIP and phase III decision pending 8

9 Group: 0utlook for on track to achieve goals Sales growth (in LC) Group & Pharma (excl. Tamiflu): mid single-digit Diagnostics: significantly above market Synergies 2010: CHF 800 m 2011: CHF 1,000 m R&D investment Core EPS growth (in LC) Slightly below 2009 level Double-digit Debt 2010: 33% reduction (revised from 25%) 2015: Aim to return to net cash position 3 yr Dividend outlook Maintained (as announced in 2008)* Barring unforeseen events; Total Tamiflu sales of up to CHF 1 bn assumed for 2010; LC=Local Currency * Continuous increase in dividend pay-out ratio over the period

10 Business update Pipeline highlights 10

11 Phase II MetMab Study: Met High NSCLC patients benefit from MetMAb + Tarceva Analysis of Met High Patients PFS, HR=0.56 OS, HR= /23 patients from the Tarceva+placebo arm who crossed over to MetMAb were Met High. Spigel et al, ESMO

12 T-DM1 vs. Herceptin + docetaxel in Breast Cancer Potential for lower rate of chemo-related side effects T-DM1 (n=67) Trastuzumab + Docetaxel (n=70) Patients with an Objective Response 32 (47.8%) 29 (41.4%) Safety Evaluable Patients (n=67) (n=68) Any AE, n (%) 63 (94.0) 68 (100.0) Grade 3 AE 25 (37.3) 51 (75.0) Three most common AEs (any grade) in trastuzumab + docetaxel arm: Alopecia (hair loss) Neutropenia (reduction white blood cells) Diarrhea 1 (1.5) 5 (7.5) 7 (10.4) 45 (66.2) 39 (57.4) 31 (45.6) ESMO

13 Phase II BRAF Inhibitor (RG7204)* in Mutation Positive Metastatic Melanoma Tumor Regression (Target Lesions) Occurred in Majority of Patients (IRC) RECIST 30% Decrease *** 7 patients had 100% tumor shrinkage, 3 of which had confirmed Complete Response (CR); 1 patient had unconfirmed CR and 3 patients had non-target lesions present 122 patients had baseline and 1post-baseline scan with measurable disease *** * Developed in collaboration with Plexxikon Inc. 13

14 BRAF Mutation Analysis for Patient Selection FFPE Tumor Block Tissue Preparation Genomic DNA Extraction cobas 4800 BRAF V600 Mutation Test (in development as companion diagnostic) Designed to detect V600E (1799 T>A) mutation Samples analyzed at central labs Average turnaround from sample receipt to test result < 5 days BRAF V600E 5 TaqMan Real-time PCR 5 BRAF WT 324 samples screened; 183 mutationpositive (56%) Normalized Fluorescence Normalized Fluorescence Cycles -1 Cycles 14

15 Ocrelizumab phase II RRMS 24-week data results Gd-enhancing T1 lesions ARR* at week 24 Lesions on MRI by week (ITT): average imputation P= p< for both ocrelizumab doses vs placebo P= % 73% Primary endpoint Placebo (n=54) IFN beta-1a (n=52) Weeks Ocrelizumab 600 mg (n=51) Ocrelizumab 2000 mg (n=52) 0-24 weeks n=54 n=55 n=55 n=54 Li et al, ECTRIMS 2010 * Annualized Relapse Rate 15

16 Short-term newsflow Progress of New Molecular Entities Ocrelizumab in Multiple Sclerosis randomised phase II in RRMS ECTRIMS (15 October, Gothenburg) GA101 in Non-Hodgkin s Lymphoma phase II data in anhl ASH (December 4-7, Orlando) Nucleoside Polymerase inh. in HCV phase IIb PROPEL interim data AASLD (October 28-Nov 2, Boston) BRAF inh. in 2 nd /3 rd line melanoma single arm phase II (BRIM-2) Intl. Melanoma Congress (November 4-9, Sydney) GRI in Schizophrenia randomised phase II ACNP (December 5-9, Miami) Pertuzumab in neoadj. HER2+Breast Cancer randomised phase II NEOSPHERE SABCS (December 8-12, San Antonio) Roche's Late Stage Pipeline Update Focus on data presented at ESMO, ECTRIMS, ASH, International Melanoma Congress and ACNP London, December 9th,

17 Roche in brief Unique high-tech healthcare investment Clear strategy Biotech-based; medically-differentiated products; poised to become leader in Personalized Healthcare Attractive risk profile Limited patent risk; lowest among large-cap biotech & pharma Late stage pipeline progressing well with up to 14 new molecular entities Assets in place for sustained success New Rheumatology & Autoimmune franchise Emerging franchise in Metabolism & Diabetes; earlier-stage compounds in CNS (FPI expected to GlyT-I Phase III by year-end) Unique high-tech healthcare investment 17

18 We Innovate Healthcare 18

Translating excellence in science into customer benefit. Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals

Translating excellence in science into customer benefit. Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals Translating excellence in science into customer benefit Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals Barclays Healthcare Conference, Miami March 16, 2011 This presentation contains certain

More information

Roche. Pascal Soriot COO Roche Pharmaceuticals

Roche. Pascal Soriot COO Roche Pharmaceuticals 1 Roche Pascal Soriot COO Roche Pharmaceuticals 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,

More information

Roche Committed to innovation and profitable growth. Dr. Alan Hippe CFO Roche. Zurich, May 2011

Roche Committed to innovation and profitable growth. Dr. Alan Hippe CFO Roche. Zurich, May 2011 Roche Committed to innovation and profitable growth Dr. Alan Hippe CFO Roche Zurich, May 2011 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified

More information

Roche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011

Roche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,

More information

Diagnostics Division. Daniel O Day COO Roche Diagnostics

Diagnostics Division. Daniel O Day COO Roche Diagnostics 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,

More information

Roche Diagnostics. Daniel O Day COO Roche Diagnostics. Vontobel Summer Conference June 22, 2012

Roche Diagnostics. Daniel O Day COO Roche Diagnostics. Vontobel Summer Conference June 22, 2012 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,

More information

Innovation and value creation. Severin Schwan, CEO Roche Group. Zurich, January 2015

Innovation and value creation. Severin Schwan, CEO Roche Group. Zurich, January 2015 Innovation and value creation Severin Schwan, CEO Roche Group Zurich, January 2015 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words

More information

Diagnostics Division. Daniel O Day COO Roche Diagnostics

Diagnostics Division. Daniel O Day COO Roche Diagnostics 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,

More information

Focus and value creation

Focus and value creation Focus and value creation Karl Mahler: Head IR Stefan Frings: Medical Affairs Director Germany London, November 2014 This presentation contains certain forward-looking statements. These forward-looking

More information

Roche: Committed to Innovation

Roche: Committed to Innovation Roche: Committed to Innovation William M. Burns CEO Roche Pharmaceuticals UBS Swiss Equity Conference, Zurich, 26. November 2009 This presentation contains certain forward-looking statements. These forward-looking

More information

Science, patient benefits and productivity

Science, patient benefits and productivity Science, patient benefits and productivity Alan Hippe, CFO Roche Group London, November 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified

More information

Roche: Building on strength

Roche: Building on strength Roche: Building on strength Erich Hunziker, Deputy Head of the Corporate Executive Committee and CFO 1 This presentation contains certain forward-looking statements. These forward-looking statements may

More information

Nine months ended 30 September At CER* In CHF In USD Pharmaceuticals Division Excluding Tamiflu 24,397 24,096 28,395 27,587

Nine months ended 30 September At CER* In CHF In USD Pharmaceuticals Division Excluding Tamiflu 24,397 24,096 28,395 27,587 Media Release Basel, 3 October 20 Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches Group sales rise 2% at CER (-2% in Swiss

More information

Dr. Karl Mahler, Head of Investor Relations Dr. Stefan Frings, Life Cycle Leader Avastin

Dr. Karl Mahler, Head of Investor Relations Dr. Stefan Frings, Life Cycle Leader Avastin Roche Positioning AVASTIN-based therapy as essential to treat cancer Dr. Karl Mahler, Head of Investor Relations Dr. Stefan Frings, Life Cycle Leader This presentation contains certain forward-looking

More information

Roche delivers good sales growth in the first nine months of 2016

Roche delivers good sales growth in the first nine months of 2016 Investor Update Basel, 20 October 2016 Roche delivers good sales growth in the first nine months of 2016 Group sales increase 4% 1 at constant exchange rates, 6% in Swiss francs Pharmaceuticals Division

More information

Roche Group posts strong sales growth in the third quarter. Cancer medicines and clinical lab business drive Group performance

Roche Group posts strong sales growth in the third quarter. Cancer medicines and clinical lab business drive Group performance Media Release Basel, 16 October 2012 Roche Group posts strong sales growth in the third quarter Group sales rise 4% at CER 1 to 33.7 billion Swiss francs (+7% in Swiss francs) in the first nine months

More information

Pascal Soriot, Head of Strategic Marketing

Pascal Soriot, Head of Strategic Marketing Workshop Marketing a cancer drug Pascal Soriot, Head of Strategic Marketing Trends in the oncology market Europe/ RoW compared to US Marketing cancer drugs successfully Leveraging 1 st mover advantage

More information

Roche A sustainable business model based on innovation and productivity gains. Karl Mahler, Head of Investor Relations

Roche A sustainable business model based on innovation and productivity gains. Karl Mahler, Head of Investor Relations Roche A sustainable business model based on innovation and productivity gains Karl Mahler, Head of Investor Relations 1 This presentation contains certain forward-looking statements. These forward-looking

More information

Sales CHF millions As % of sales % change. In CHF Group sales 12,942 12,

Sales CHF millions As % of sales % change. In CHF Group sales 12,942 12, Investor Update Basel, 27 April 2017 Roche reports a good start in 2017 Group sales increase 4% 1 at constant exchange rates and in Swiss francs Pharmaceuticals Division sales up 3%, driven mainly by Tecentriq

More information

UBS European Conference 2013

UBS European Conference 2013 UBS European Conference 2013 Tuesday, 12 November 2013 Karl Mahler, Head of Investor Relations Stefan Frings, Oncology/Immunology Therapeutic Area Head,Roche Partnering Group: Continued strong sales growth

More information

Investor Update. Roche in 2011: Strong results and positive outlook. Basel, 1 February 2012

Investor Update. Roche in 2011: Strong results and positive outlook. Basel, 1 February 2012 Investor Update Basel, February 0 Roche in : Strong results and positive outlook Group sales rise % (-0% in Swiss francs; +6% in US dollars), excluding Tamiflu. Significant foreign exchange impact of percentage

More information

Sales CHF millions As % of sales % change. January - March CER CHF Group sales 13,583 12,

Sales CHF millions As % of sales % change. January - March CER CHF Group sales 13,583 12, Investor Update Basel, 26 April 2018 Roche reports a strong start in 2018 Group sales increase 6% 1 at constant exchange rates and 5% in Swiss francs Pharmaceuticals Division sales up 7%, driven mainly

More information

Helvea Swiss Equities Conference, January 15, 2010

Helvea Swiss Equities Conference, January 15, 2010 Translating excellence in science into customer benefit Dr. Karl Mahler, Head of Investor Relations Dr. Stefan Frings, Global Product Strategy - Avastin Franchise Leader Helvea Swiss Equities Conference,

More information

Roche Group s first-quarter 2011 sales on track for full-year targets positive results in seven key clinical trials

Roche Group s first-quarter 2011 sales on track for full-year targets positive results in seven key clinical trials Media Release Basel, 14 April 2011 Roche Group s first-quarter 2011 sales on track for full-year targets positive results in seven key clinical trials Group Group sales stable in local currencies (-9%

More information

Slide 1. Investor presentation. London 5 February 2019

Slide 1. Investor presentation. London 5 February 2019 Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation

More information

Roche at a Glance An Introduction to our Company. February 2013

Roche at a Glance An Introduction to our Company. February 2013 Roche at a Glance An Introduction to our Company February 2013 Basic facts at a glance Founded 1896 in Basel, Switzerland Founding families still hold majority stake Employing 80,000 people Currently active

More information

Clinical Development at Roche: Driving the paradigm shift

Clinical Development at Roche: Driving the paradigm shift Clinical Development at Roche: Driving the paradigm shift Jean-Jacques Garaud, MD Global Head Pharma Development, Chief Medical Officer Roche UBS Global Life Science Conference, New York, September 22,

More information

Roche on track for full-year targets good sales growth in first quarter

Roche on track for full-year targets good sales growth in first quarter Investor Update Basel, 12 April 2012 Roche on track for full-year targets good sales growth in first quarter Group sales rise 2% at CER 1 (-1% in Swiss francs; +1% in US dollars) to 11.0 billion Swiss

More information

Third Quarter 2015 Earnings Call. November 9, 2015

Third Quarter 2015 Earnings Call. November 9, 2015 Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements

More information

2. Quarterly sales and constant exchange rate sales growth by Division in 2016 and

2. Quarterly sales and constant exchange rate sales growth by Division in 2016 and Appendix: Tables 1. Sales January to March 2016 and 2015... 2 2. Quarterly sales and constant exchange rate sales growth by Division in 2016 and 2015... 3 3. Pharmaceuticals Division... 4 4. Top 20 Pharmaceuticals

More information

Roche Committed to Innovation

Roche Committed to Innovation Roche Committed to Innovation Jean-Jacques Garaud, M.D. Global Head of pharma. Research & Exploratory Development Roche Pharmaceuticals Exane BNP Paribas Healthcare Conference May 10, 2010, Paris 1 Roche:

More information

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER

More information

January March CHF m CHF m In CHF

January March CHF m CHF m In CHF 1. Sales January to March 2011 and 2010 2011 2010 % change January March CHF m CHF m In CHF In local currencies Pharmaceuticals Division 8,712 9,727-10 -2 United States 3,322 3,647-9 +2 Western Europe

More information

Roche reports strong sales growth in the first nine months of Sales CHF millions As % of sales % change

Roche reports strong sales growth in the first nine months of Sales CHF millions As % of sales % change Investor Update Basel, 19 October 2017 Roche reports strong sales growth in the first nine months of 2017 Group sales increase 5% 1 at constant exchange rates and in Swiss francs Pharmaceuticals Division

More information

Committed to innovation and growth

Committed to innovation and growth Committed to innovation and growth Stefan Frings - Medical Director Germany London November 2016 2 This presentation contains certain forward-looking statements. These forward-looking statements may be

More information

Committed to innovation and growth

Committed to innovation and growth Committed to innovation and growth Karl Mahler Head of Investor Relations Bill Anderson Head of Global Product Strategy June 2013 This presentation contains certain forward-looking statements. These forward-looking

More information

Innovation and growth

Innovation and growth Innovation and growth Alan Hippe, CFO Roche Group Jefferies Healthcare Conference, June 2014 Performance update Industry in context Building pillars of growth / ASCO 2014 Summary 2 Q1 2014: Strong sales

More information

Oncology Therapeutics without Compromise APRIL 2011

Oncology Therapeutics without Compromise APRIL 2011 Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within

More information

Innovation and growth

Innovation and growth Innovation and growth Bill Anderson Head of Global Product Strategy and Chief Marketing Officer Jefferies Healthcare Conference London, November 2014 This presentation contains certain forward-looking

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation

More information

Review of Half Year 2010

Review of Half Year 2010 Aiming i to Become a Top Japanese Pharmaceutical Company Review of Half Year 2010 CHUGAI PHARMACEUTICAL CO., LTD. President and CEO Osamu Nagayama July 22/23, 2010 Forward-Looking Statementst t Aiming

More information

Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011

Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011 Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee

More information

Roche delivers continued growth in the first half of 2016

Roche delivers continued growth in the first half of 2016 Investor Update Basel, 21 July 2016 Roche delivers continued growth in the first half of 2016 Group sales increased by 5% 1 at constant exchange rates, 6% in Swiss francs Pharmaceuticals Division sales

More information

Core earnings per share up 7% at constant exchange rates, 0% in Swiss francs

Core earnings per share up 7% at constant exchange rates, 0% in Swiss francs Investor Update Basel, 24 July 2014 Roche with good half year performance Group sales up 5% at constant exchange rates 1, -1% in Swiss francs Core earnings per share up 7% at constant exchange rates, 0%

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical

More information

Innovation and value creation

Innovation and value creation Innovation and value creation Severin Schwan, CEO Roche Bank am Bellevue Zuerich, January 2017 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified

More information

Roche First quarter 2010 sales. April 15, 2010

Roche First quarter 2010 sales. April 15, 2010 1 Roche First quarter 2010 sales April 15, 2010 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,

More information

Investor Update. Roche posts strong first-half results. Úten morgen her speck! Basel, 25 July 2013

Investor Update. Roche posts strong first-half results. Úten morgen her speck! Basel, 25 July 2013 Investor Update Úten morgen her speck! Basel, 25 July 2013 Roche posts strong first-half results Group sales 5% 1 higher at 23.3 billion Swiss francs Core EPS 12% higher at 7.58 Swiss francs; net income

More information

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

Core earnings per share up 7% at constant exchange rates, 0% in Swiss francs

Core earnings per share up 7% at constant exchange rates, 0% in Swiss francs Media Release Basel, 24 July 2014 Roche with good half year performance Group sales up 5% at constant exchange rates 1, -1% in Swiss francs Core earnings per share up 7% at constant exchange rates, 0%

More information

Roche: Committed to Innovation. William M. Burns, CEO Roche Pharmaceuticals

Roche: Committed to Innovation. William M. Burns, CEO Roche Pharmaceuticals Roche: Committed to Iovation William M. Burns, CEO Roche Pharmaceuticals This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such

More information

Roche. Q Sales. April 14, 2011 Basel

Roche. Q Sales. April 14, 2011 Basel Roche Q1 2011 Sales April 14, 2011 Basel 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,

More information

Basel, October 17, 2006

Basel, October 17, 2006 Roche Third quarter 2006 Basel, October 17, 2006 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,

More information

Roche First quarter Roche First Quarter 2007 Apr. 18,

Roche First quarter Roche First Quarter 2007 Apr. 18, r Roche First quarter 2007 April 18, 2007 Apr. 18, 2007 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects,

More information

Roche Annual Results 2008 February 2009 Basel, London, New York. Roche Full Year Results 2008 February 4, 2009

Roche Annual Results 2008 February 2009 Basel, London, New York. Roche Full Year Results 2008 February 4, 2009 1 Roche Annual Results 2008 February 2009 Basel, London, New York This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes,

More information

Media Release. FDA grants Roche s Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer

Media Release. FDA grants Roche s Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer Media Release Basel, 1 October 2013 FDA grants Roche s Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer The Perjeta regimen is the first treatment

More information

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated

More information

Developing & Commercializing Targeted Small Molecule Drugs in Cancer

Developing & Commercializing Targeted Small Molecule Drugs in Cancer Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions

More information

Committed to innovation and growth

Committed to innovation and growth Committed to innovation and growth Karl Mahler Head of Investor Relations Stefan Frings Oncology/Immunology Therapeutic Area Head Roche Partnering Roche Group June 2013 This presentation contains certain

More information

Idenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston

Idenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements

More information

Roche reports strong performance in the first half of 2017

Roche reports strong performance in the first half of 2017 Investor Update Basel, 27 July 2017 Roche reports strong performance in the first half of 2017 Group sales increase 5% 1 at constant exchange rates and in Swiss francs Pharmaceuticals Division sales up

More information

Operating free cash flow rises 10% to 15.4 billion Swiss francs. HER2-franchise strengthened by Perjeta launch, filing of T-DM1 in US and Europe

Operating free cash flow rises 10% to 15.4 billion Swiss francs. HER2-franchise strengthened by Perjeta launch, filing of T-DM1 in US and Europe Media Release Yes, let s see, may Basel, 30 January 2013 Roche delivers strong 2012 results Group sales rise 4% 1 to 45.5 billion Swiss francs due to oncology sales, clinical laboratory business Core EPS

More information

First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress

First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Media Release Basel, 03 October 2016 First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Superiority results from the phase

More information

Investor Presentation

Investor Presentation Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance

More information

Roche: Defining priorities for a high tech healthcare company

Roche: Defining priorities for a high tech healthcare company Roche: Defining priorities for a high tech healthcare company Erich Hunziker, Deputy Head of the Corporate Executive Committee and CFO October 2007 1 This presentation contains certain forward-looking

More information

Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004

Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations

More information

Rejuvenating the portfolio

Rejuvenating the portfolio Rejuvenating the portfolio Severin Schwan CEO Bernstein Strategic Conference, New York, May 2018 This presentation contains certain forward-looking statements. These forward-looking statements may be identified

More information

Media Release. Basel, 3 June 2012

Media Release. Basel, 3 June 2012 Media Release Basel, 3 June 2012 Roche s targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III

More information

Genta Incorporated. A Multiproduct Late-Stage Oncology Company

Genta Incorporated. A Multiproduct Late-Stage Oncology Company Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking

More information

Appendix: Tables Full-Year 2011

Appendix: Tables Full-Year 2011 Basel, 1 February 2012 Appendix: Tables Full-Year 2011 Contents 1. Pharmaceuticals Division major clinical trials in 2011... 2 2. Pharmaceuticals Division major regulatory approvals in 2011... 5 3. Pharmaceuticals

More information

Building a Fully Integrated Biopharmaceutical Company. June 2014

Building a Fully Integrated Biopharmaceutical Company. June 2014 Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation

More information

Kapil Dhingra, VP,Head Oncology DBA

Kapil Dhingra, VP,Head Oncology DBA Lehman Global Healthcare Conference 18 March 2008, Miami Kapil Dhingra, VP,Head Oncology DBA Forward-looking statements This presentation contains certain forward-looking statements. These forward-looking

More information

Roche YTD September 2007 October 16, 2007

Roche YTD September 2007 October 16, 2007 Roche YTD September 2007 October 16, 2007 October 16, 2007 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes,

More information

1 Pharmaceutical Division 42, Diagnostics Division 32,794 9,737

1 Pharmaceutical Division 42, Diagnostics Division 32,794 9,737 Investor Update Yes, let s see, may Basel, 30 January 2013 Roche delivers strong 2012 results Group sales rise 4% 1 to 45.5 billion Swiss francs due to oncology sales, clinical laboratories business Core

More information

Roche: defining priorities for a high tech healthcare company

Roche: defining priorities for a high tech healthcare company Roche: defining priorities for a high tech healthcare company Erich Hunziker, CFO and Deputy Head of the Corporate Executive Committee June 2007 1 This presentation contains certain forward-looking statements.

More information

Media Release. Roche committed to innovation and growth. Basel and London, 5 September 2012

Media Release. Roche committed to innovation and growth. Basel and London, 5 September 2012 Media Release Basel and London, 5 September 2012 Roche committed to innovation and growth Personalised healthcare leadership and world-class pipeline presented at investor conference Industry-leading pipeline

More information

International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1

International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1 Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking

More information

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year

More information

July, ArQule, Inc.

July, ArQule, Inc. July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical

More information

Core EPS growth ahead of sales, up 10% to Swiss francs

Core EPS growth ahead of sales, up 10% to Swiss francs Investor Update Basel, 30 January 2014 Roche delivers strong 2013 results Group sales rise 6% 1 to 46.8 billion Swiss francs Pharmaceuticals sales 7% higher, driven by HER2 breast cancer franchise, Avastin,

More information

Roche delivers strong performance in the first half of 2015

Roche delivers strong performance in the first half of 2015 Investor Update Basel, 23 July Roche delivers strong performance in the first half of 2015 Group sales up 6% at constant exchange rates 1, 3% in Swiss francs Pharmaceuticals Division sales up 5%, driven

More information

A world leader in allergy immunotherapy

A world leader in allergy immunotherapy A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader

More information

Diagnostics Division Daniel O Day COO Roche Diagnostics

Diagnostics Division Daniel O Day COO Roche Diagnostics Diagnostics Division Daniel O Day COO Roche Diagnostics 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects,

More information

FY2007 Consolidated Financial Overview

FY2007 Consolidated Financial Overview FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking

More information

Media Release. Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma. Basel, 22 September 2017

Media Release. Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma. Basel, 22 September 2017 Media Release Basel, 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which

More information

Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer

Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies

More information

Roche. Q sales. April 11, 2013

Roche. Q sales. April 11, 2013 1 Roche Q1 2013 sales April 11, 2013 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,

More information

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking

More information

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with

More information

Committed to innovation and growth - sustained leadership in oncology

Committed to innovation and growth - sustained leadership in oncology Committed to innovation and growth - sustained leadership in oncology UBS European Conference 2012 November 13, 2012 Dr. K. Mahler, Head of Investor Relations Dr. Stefan Frings, Global Head Medical Affairs

More information

SUMMARY. Risk Level * ,214 A ,583 A ,674 E ,710 E

SUMMARY. Risk Level * ,214 A ,583 A ,674 E ,710 E February 6, 2015 Roche Holding AG Current Recommendation Prior Recommendation Neutral Date of Last Change 02/06/2015 Current Price (02/05/15) $33.81 Target Price $31.00 UNDERPERFORM SUMMARY (RHHBY-OTC)

More information

Media Release. Basel, 7 November 2013

Media Release. Basel, 7 November 2013 Media Release Basel, November 2013 Roche s Gazyva helped people with one of the most common forms of blood cancer live significantly longer without their disease worsening compared to MabThera/Rituxan

More information

Rejuvenating the portfolio

Rejuvenating the portfolio Rejuvenating the portfolio Alan Hippe CFO dbaccess Berlin Conference, June 2018 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words

More information

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo

More information

ESMO IO Congress 2017, Geneva. Roche Analyst Call. Thursday, 7 December 2017

ESMO IO Congress 2017, Geneva. Roche Analyst Call. Thursday, 7 December 2017 ESMO IO Congress 2017, Geneva Roche Analyst Call Thursday, 7 December 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Building a Premier Oncology Biotech September 2017 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements

More information

CHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma

CHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma Media Release Basel, 29 April 2016 CHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma In the pivotal study, treatment with Gazyvaro plus bendamustine

More information